La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Immunovia Gestione

Gestione criteri di controllo 0/4

Immunovia's Il CEO è Jeff Borcherding, nominato in Apr2023, ha un mandato di 1.33 anni. possiede direttamente 0.77% delle azioni della società, per un valore di SEK 311.50K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.5 anni e 4.3 anni.

Informazioni chiave

Jeff Borcherding

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	1.4yrs
Proprietà del CEO	0.2%
Durata media del management	1.6yrs
Durata media del Consiglio di amministrazione	2.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Here's Why We're Not Too Worried About Immunovia's (STO:IMMNOV) Cash Burn Situation

Jan 18

We Think Immunovia (STO:IMMNOV) Can Afford To Drive Business Growth

Aug 28

What Kind Of Investors Own Most Of Immunovia AB (publ) (STO:IMMNOV)?

Mar 09

Here's Why We're Not Too Worried About Immunovia's (STO:IMMNOV) Cash Burn Situation

Feb 03

Immunovia AB (publ)'s (STO:IMMNOV) Intrinsic Value Is Potentially 72% Above Its Share Price

Dec 30

Insider Buying: The Immunovia AB (publ) (STO:IMMNOV) Director Just Bought kr293k Worth Of Shares

Dec 03

AMMINISTRATORE DELEGATO

Jeff Borcherding (51 yo)

1.4yrs

Mandato

Mr. Jeff Borcherding served as Chief Executive Officer of US, Immunovia, Inc. at Immunovia AB (publ) since 2022 until April 2023. He serves as Global Chief Executive Officer of Immunovia AB (publ) since Ap...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Jeff Borcherding	Global Chief Executive Officer & President	1.4yrs	Nessun dato	0.21% SEK 188.7k
Karin Liwendahl	Chief Financial Officer	2.4yrs	Nessun dato	Nessun dato
Lara Sucheston-Campbell	Head of Clinical & Medical Affairs	1.6yrs	Nessun dato	Nessun dato

1.6yrs

Durata media

Gestione esperta: Il team dirigenziale di IMMNOV non è considerato esperto (durata media 1.5 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Peter Hongaard Andersen	Independent Chairman	4.3yrs	SEK 475.00k	Nessun dato
Hans Johansson	Independent Director	8.7yrs	SEK 280.00k	0.027% SEK 24.9k
Michael Lofman	Independent Director	1.3yrs	SEK 175.00k	Nessun dato
Valerie Bogdan-Powers	Independent Director	less than a year	SEK 16.00k	Nessun dato
Melissa Farina	Independent Director	less than a year	SEK 16.00k	Nessun dato
Martin Moller	Independent Director	3.3yrs	SEK 302.00k	Nessun dato

2.3yrs

Durata media

57yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di IMMNOV non è considerato esperto (durata media del mandato 2.3 anni), il che suggerisce un nuovo consiglio.

Immunovia Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Immunovia AB (Publ) Elects Melissa Farina and Valerie Bogdan-Powers as New Board Members

Immunovia AB (publ) Announces Board Changes

Immunovia AB (Publ) Announces Board Changes

Philipp Von Hugo Resigns from Immunovia's Board at His Own Request

Immunovia AB (Publ) Appoints Lara E. Sucheston-Campbell as the Head of Clinical and Medical Affairs, Effective February 1, 2023

Immunovia Inc. Appoints Jon Hager as New National Sales Director

Recent updates

New major risk - Shareholder dilution

New major risk - Shareholder dilution

Second quarter 2024 earnings released: kr0.56 loss per share (vs kr4.00 loss in 2Q 2023)

Immunovia AB (publ) Announces the Next-Generation Test to Be Included in Large Study of Pancreatic Cysts funded by the U.S. National Institutes of Health

Immunovia Files US Patent Application to Protect Its Next-Generation Test

Immunovia Completes Development of Its Pancreatic Cancer Detection Test After Substantially Increasing Test Accuracy

Immunovia AB Presents Detailed Discovery Study Results for its Next-Generation Early Detection Test for Pancreatic Cancer at PancreasFest 2024 Annual Meeting

Immunovia AB (publ) to Report Fiscal Year 2024 Results on Feb 25, 2025

Immunovia Streamlines Lab Operations with Move to Research Triangle Park, North Carolina

Immunovia AB Announces Positive Results from the Model-Development Study for Its Next-Generation Pancreatic Cancer Detection Test

Immunovia Successfully Develops Assays to Measure Targeted Proteomedix for Its Next-Generation Pancreatic Cancer Test - Moving Forward Towards Model-Development Study

Full year 2023 earnings released: kr7.95 loss per share (vs kr7.43 loss in FY 2022)

Immunovia AB (publ) to Report Q3, 2024 Results on Nov 14, 2024

Immunovia AB (Publ) Elects Melissa Farina and Valerie Bogdan-Powers as New Board Members

Third quarter 2023 earnings released: kr0.91 loss per share (vs kr1.01 loss in 3Q 2022)

Immunovia Successfully Completes Discovery Phase of Next-Generation Test Development

Immunovia to Significantly Restructure to Focus Resources on its Next-Generation Blood Test for Pancreatic Cancer Detection

New major risk - Revenue and earnings growth

Immunovia AB (publ) Announces Board Changes

First quarter 2023 earnings released: kr2.28 loss per share (vs kr1.95 loss in 1Q 2022)

Immunovia AB (Publ) Announces Board Changes

Philipp Von Hugo Resigns from Immunovia's Board at His Own Request

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Here's Why We're Watching Immunovia's (STO:IMMNOV) Cash Burn Situation

Forecast to breakeven in 2024

Immunovia Realigning Swedish Operations with Strategic Priorities and its Focus on the US Commercialization of the Immray Pancan-D Test

Immunovia AB (Publ) Appoints Lara E. Sucheston-Campbell as the Head of Clinical and Medical Affairs, Effective February 1, 2023

We're Keeping An Eye On Immunovia's (STO:IMMNOV) Cash Burn Rate

Immunovia Inc. Appoints Jon Hager as New National Sales Director

Forecast to breakeven in 2024

Price target decreased to kr110

Immunovia AB (publ), Annual General Meeting, Apr 27, 2023

Immunovia AB (Publ) Announces Appointment of Nomination Committee for the 2023 Annual General Meeting

Immunovia AB Announces Executive Management Team Appointments

Immunovia AB Announces Positive Update on Physician Experience Program with IMMrayTM PanCan-d

Immunovia AB Issues Preliminary Payment Rate Determination for IMMray PanCan-D Test

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Immunovia, Inc. Receives Clinical and Public Health Laboratory License from California Dept of Public Health for IMMray Pancan-d Test

Immunovia AB Announces PanDIA-1 Study for Early Detection of Pancreatic Cancer in Newly Onset Type Diabetics Moves into Next Phase

Immunovia AB Announces Results from PanFAM-1 Study

Immunovia AB (publ) Announces Executive Changes

Immunovia Names Philipp Mathieu as Chief Executive Officer

Immunovia AB Appoints Natalie Carfora as Head of Market Access US Subsidiary

Is Immunovia (STO:IMMNOV) In A Good Position To Invest In Growth?

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Immunovia AB (Publ) Announces Board Changes

Independent Director recently bought kr186k worth of stock

Price target decreased to kr215

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues miss analyst expectations

Here's Why We're Not Too Worried About Immunovia's (STO:IMMNOV) Cash Burn Situation

Third quarter 2021 earnings released: kr1.60 loss per share (vs kr1.68 loss in 3Q 2020)

Price target increased to kr298

We Think Immunovia (STO:IMMNOV) Can Afford To Drive Business Growth

Second quarter 2021 earnings released: kr2.18 loss per share (vs kr1.67 loss in 2Q 2020)

Immunovia AB (publ) Receives Approval to Begin Testing Patients for Pancreatic Cancer with the Immrayt Pancan-D Test

Chief Executive Officer recently bought kr676k worth of stock

Price target increased to kr300

Independent Director recently bought kr298k worth of stock

Independent Director has left the company

Independent Director recently bought kr192k worth of stock

First quarter 2021 earnings released: kr1.04 loss per share (vs kr1.41 loss in 1Q 2020)

Full year 2020 earnings released: kr6.84 loss per share (vs kr5.85 loss in FY 2019)

New 90-day high: kr131

What Kind Of Investors Own Most Of Immunovia AB (publ) (STO:IMMNOV)?

Iimmunovia AB (Publ) Publishes Data Sets on the Optimization Study and Commercial Test Model Study

Full year 2020 earnings released: kr6.84 loss per share (vs kr5.85 loss in FY 2019)

Earnings miss expectations

Immunovia AB (publ) to Report Q1, 2021 Results on Apr 28, 2021